Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism

Peptides

Volumn 100, Issue , 2018, Pages 158-164

  Mulvihill, Erin E ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Dipeptidyl peptidase 4; Dyslipidemia; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretins; Soluble DPP4; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INCRETIN; DPP4 PROTEIN, HUMAN; GLUCOSE;

ADIPOSE TISSUE; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INTESTINE; KIDNEY; LIPID METABOLISM; LIVER TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCOSE; HUMANS; INCRETINS; LIPID METABOLISM; POSTPRANDIAL PERIOD;

EID: 85041458842     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2017.11.023     Document Type: Review

References (104)

1. Lee, Y.H., Wang, M.Y., Yu, X.X., Unger, R.H., Glucagon is the key factor in the development of diabetes. Diabetologia 59:7 (2016), 1372–1375.
2. Otero, Y.F., Stafford, J.M., McGuinness, O.P., Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux. J. Biol. Chem. 289:30 (2014), 20462–20469.
3. Seino, Y., Fukushima, M., Yabe, D., GIP and GLP-1, the two incretin hormones: similarities and differences. J. Diabetes Investig. 1:1–2 (2010), 8–23.
4. Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87:4 (2007), 1409–1439.
5. Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132:6 (2007), 2131–2157.
6. Ogata, S., Misumi, Y., Ikehara, Y., Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. J. Biol. Chem. 264:6 (1989), 3596–3601.
7. Mulvihill, E.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35:6 (2014), 992–1019.
8. Lambeir, A.M., Durinx, C., Scharpe, S., De Meester, I., Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40:3 (2003), 209–294.
9. Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D.M., Eckardt, K., Kaufman, J.M., Ryden, M., Muller, S., Hanisch, F.G., Ruige, J., Arner, P., Sell, H., Eckel, J., Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60:7 (2011), 1917–1925.
10. Rohrborn, D., Eckel, J., Sell, H., Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 588:21 (2014), 3870–3877.
11. Sell, H., Bluher, M., Kloting, N., Schlich, R., Willems, M., Ruppe, F., Knoefel, W.T., Dietrich, A., Fielding, B.A., Arner, P., Frayn, K.N., Eckel, J., Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 36:12 (2013), 4083–4090.
12. Ahmed, R.H., Huri, H.Z., Muniandy, S., Al-Hamodi, Z., Al-Absi, B., Alsalahi, A., Razif, M.F., Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. Clin. Biochem. 50:13–14 (2017), 746–749.
13. Ryskjaer, J., Deacon, C.F., Carr, R.D., Krarup, T., Madsbad, S., Holst, J., Vilsboll, T., Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur. J. Endocrinol. 155:3 (2006), 485–493.
14. Anoop, S., Misra, A., Bhatt, S.P., Gulati, S., Pandey, R.M., Mahajan, H., High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-control study. BMJ Open Diabetes Res. Care, 5(1), 2017, e000393.
15. Baumeier, C., Saussenthaler, S., Kammel, A., Jahnert, M., Schluter, L., Hesse, D., Canouil, M., Lobbens, S., Caiazzo, R., Raverdy, V., Pattou, F., Nilsson, E., Pihlajamaki, J., Ling, C., Froguel, P., Schurmann, A., Schwenk, R.W., Hepatic DPP4 DNA methylation associates with fatty liver. Diabetes 66:1 (2017), 25–35.
16. Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17:4 (2013), 819–837.
17. Nauck, M., Stockmann, F., Ebert, R., Creutzfeldt, W., Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986), 46–52.
18. Nauck, M.A., Homberger, E., Siegel, E.G., Allen, R.C., Eaton, R.P., Ebert, R., Creutzfeldt, W., Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63:2 (1986), 492–498.
19. Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J.J., Schuit, F., Drucker, D.J., Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:5 (2004), 1326–1335.
20. Flock, G., Baggio, L.L., Longuet, C., Drucker, D.J., Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56:12 (2007), 3006–3013.
21. Smith, E.P., An, Z., Wagner, C., Lewis, A.G., Cohen, E.B., Li, B., Mahbod, P., Sandoval, D., Perez-Tilve, D., Tamarina, N., Philipson, L.H., Stoffers, D.A., Seeley, R.J., D'Alessio, D.A., The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 19:6 (2014), 1050–1057.
22. Iida, A., Seino, Y., Fukami, A., Maekawa, R., Yabe, D., Shimizu, S., Kinoshita, K., Takagi, Y., Izumoto, T., Ogata, H., Ishikawa, K., Ozaki, N., Tsunekawa, S., Hamada, Y., Oiso, Y., Arima, H., Hayashi, Y., Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin. Diabetologia 59:7 (2016), 1533–1541.
23. Nauck, M., Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes. Metab. 18:3 (2016), 203–216.
24. Waget, A., Cabou, C., Masseboeuf, M., Cattan, P., Armanet, M., Karaca, M., Castel, J., Garret, C., Payros, G., Maida, A., Sulpice, T., Holst, J.J., Drucker, D.J., Magnan, C., Burcelin, R., Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152:8 (2011), 3018–3029.
25. Campbell, J.E., Ussher, J.R., Mulvihill, E.E., Kolic, J., Baggio, L.L., Cao, X., Liu, Y., Lamont, B.J., Morii, T., Streutker, C.J., Tamarina, N., Philipson, L.H., Wrana, J.L., MacDonald, P.E., Drucker, D.J., TCF1 links GIPR signaling to the control of beta cell function and survival. Nat. Med. 22:1 (2016), 84–90.
26. Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Sakagami, H., Kitsunai, H., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T.J., Haneda, M., Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects. Mol. Metab. 6:2 (2017), 226–231.
27. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., Creutzfeldt, W., Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91 (1993), 301–307.
28. Lynn, F.C., Pamir, N., Ng, E.H., McIntosh, C.H., Kieffer, T.J., Pederson, R.A., Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50:5 (2001), 1004–1011.
29. Zhou, J., Livak, M.F., Bernier, M., Muller, D.C., Carlson, O.D., Elahi, D., Maudsley, S., Egan, J.M., Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am. J. Physiol. Endocrinol. Metab. 293:2 (2007), E538–E547.
30. Xu, G., Kaneto, H., Laybutt, D.R., Duvivier-Kali, V.F., Trivedi, N., Suzuma, K., King, G.L., Weir, G.C., Bonner-Weir, S., Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56:6 (2007), 1551–1558.
31. Aaboe, K., Akram, S., Deacon, C.F., Holst, J.J., Madsbad, S., Krarup, T., Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors. Diabetes Obes. Metab. 17:1 (2015), 74–81.
32. Hojberg, P.V., Vilsboll, T., Rabol, R., Knop, F.K., Bache, M., Krarup, T., Holst, J.J., Madsbad, S., Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:2 (2009), 199–207.
33. Raschke, S., Eckardt, K., Bjorklund Holven, K., Jensen, J., Eckel, J., Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS One, 8(4), 2013, e62008.
34. Nargis, T., Kumar, K., Ghosh, A.R., Sharma, A., Rudra, D., Sen, D., Chakrabarti, S., Mukhopadhyay, S., Ganguly, D., Chakrabarti, P., KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes. Mol. Metab. 6:11 (2017), 1529–1539.
35. Wronkowitz, N., Gorgens, S.W., Romacho, T., Villalobos, L.A., Sanchez-Ferrer, C.F., Peiro, C., Sell, H., Eckel, J., Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim. Biophys. Acta 1842:9 (2014), 1613–1621.
36. Lee, D.S., Lee, E.S., Alam, M.M., Jang, J.H., Lee, H.S., Oh, H., Kim, Y.C., Manzoor, Z., Koh, Y.S., Kang, D.G., Lee, D.H., Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate. Metabolism 65:2 (2016), 89–101.
37. Ambrosi, T.H., Scialdone, A., Graja, A., Gohlke, S., Jank, A.M., Bocian, C., Woelk, L., Fan, H., Logan, D.W., Schurmann, A., Saraiva, L.R., Schulz, T.J., Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell 20:6 (2017), 771–784 e6.
38. Hansen, L., Deacon, C.F., Orskov, C., Holst, J.J., Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:11 (1999), 5356–5363.
39. Mulvihill, E.E., Varin, E.M., Gladanac, B., Campbell, J.E., Ussher, J.R., Baggio, L.L., Yusta, B., Ayala, J., Burmeister, M.A., Matthews, D., Bang, K.W., Ayala, J.E., Drucker, D.J., Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis. Cell Metab. 25:1 (2017), 152–165.
40. Ahlkvist, L., Omar, B., Pacini, G., Ahren, B., Evidence for neural contribution to islet effects of DPP-4 inhibition in mice. Eur. J. Pharmacol. 780 (2016), 46–52.
41. Jensen, S.R., Wheeler, S.E., Hvid, H., Ahnfelt-Ronne, J., Hansen, B.F., Nishimura, E., Olsen, G.S., Brubaker, P.L., Elucidating the biological roles of insulin and its receptor in murine intestinal growth and function. Endocrinology 158:8 (2017), 2453–2469.
42. Wang, Z., Grigo, C., Steinbeck, J., von Horsten, S., Amann, K., Daniel, C., Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides 57 (2014), 109–117.
43. Cho, J.M., Jang, H.W., Cheon, H., Jeong, Y.T., Kim, D.H., Lim, Y.M., Choi, S.H., Yang, E.K., Shin, C.Y., Son, M.H., Kim, S.H., Kim, H.J., Lee, M.S., A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis. Diabetes Res. Clin. Pract. 91:1 (2011), 72–79.
44. Maida, A., Hansotia, T., Longuet, C., Seino, Y., Drucker, D.J., Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 137:6 (2009), 2146–2157.
45. Mu, J., Petrov, A., Eiermann, G.J., Woods, J., Zhou, Y.P., Li, Z., Zycband, E., Feng, Y., Zhu, L., Roy, R.S., Howard, A.D., Li, C., Thornberry, N.A., Zhang, B.B., Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur. J. Pharmacol. 623:1–3 (2009), 148–154.
46. Shah, P., Ardestani, A., Dharmadhikari, G., Laue, S., Schumann, D.M., Kerr-Conte, J., Pattou, F., Klein, T., Maedler, K., The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J. Clin. Endocrinol. Metab. 98:7 (2013), E1163–E1172.
47. van Genugten, R.E., van Raalte, D.H., Diamant, M., Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes. Metab. 14:2 (2012), 101–111.
48. Vargova, L., Zacharovova, K., Dovolilova, E., Vojtova, L., Cimburek, Z., Saudek, F., The effects of DPP-IV inhibition in NOD mice with overt diabetes. Folia Biol. (Praha) 59:3 (2013), 116–122.
49. DiGruccio, M.R., Mawla, A.M., Donaldson, C.J., Noguchi, G.M., Vaughan, J., Cowing-Zitron, C., van der Meulen, T., Huising, M.O., Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets. Mol. Metab. 5:7 (2016), 449–458.
50. Poulsen, M.D., Hansen, G.H., Dabelsteen, E., Hoyer, P.E., Noren, O., Sjostrom, H., Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells. J. Histochem. Cytochem. 41:1 (1993), 81–88.
51. Omar, B.A., Liehua, L., Yamada, Y., Seino, Y., Marchetti, P., Ahren, B., Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 57:9 (2014), 1876–1883.
52. Grondin, G., Hooper, N.M., LeBel, D., Specific localization of membrane dipeptidase and dipeptidyl peptidase IV in secretion granules of two different pancreatic islet cells. J. Histochem. Cytochem. 47:4 (1999), 489–498.
53. Augstein, P., Naselli, G., Loudovaris, T., Hawthorne, W.J., Campbell, P., Bandala-Sanchez, E., Rogers, K., Heinke, P., Thomas, H.E., Kay, T.W., Harrison, L.C., Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells. Diabetes Res. Clin. Pract. 110:3 (2015), 291–300.
54. Ackermann, A.M., Wang, Z., Schug, J., Naji, A., Kaestner, K.H., Integration of ATAC-seq and RNA-seq identifies human alpha cell and beta cell signature genes. Mol. Metab. 5:3 (2016), 233–244.
55. Marchetti, P., Lupi, R., Bugliani, M., Kirkpatrick, C.L., Sebastiani, G., Grieco, F.A., Del Guerra, S., D'Aleo, V., Piro, S., Marselli, L., Boggi, U., Filipponi, F., Tinti, L., Salvini, L., Wollheim, C.B., Purrello, F., Dotta, F., A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55:12 (2012), 3262–3272.
56. Kahles, F., Meyer, C., Mollmann, J., Diebold, S., Findeisen, H.M., Lebherz, C., Trautwein, C., Koch, A., Tacke, F., Marx, N., Lehrke, M., GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63:10 (2014), 3221–3229.
57. Kilimnik, G., Kim, A., Steiner, D.F., Friedman, T.C., Hara, M., Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic alpha-cells in mouse models of ss-cell regeneration. Islets 2:3 (2010), 149–155.
58. O'Malley, T.J., Fava, G.E., Zhang, Y., Fonseca, V.A., Wu, H., Progressive change of intra-islet GLP-1 production during diabetes development. Diabetes Metab. Res. Rev. 30:8 (2014), 661–668.
59. Whalley, N.M., Pritchard, L.E., Smith, D.M., White, A., Processing of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism enabling GLP-1 to act on beta-cells?. J. Endocrinol. 211:1 (2011), 99–106.
60. Chambers, A.P., Sorrell, J.E., Haller, A., Roelofs, K., Hutch, C.R., Kim, K.S., Gutierrez-Aguilar, R., Li, B., Drucker, D.J., D'Alessio, D.A., Seeley, R.J., Sandoval, D.A., The role of pancreatic preproglucagon in glucose homeostasis in mice. Cell Metab. 25 (2017), 927–934.
61. Traub, S., Meier, D.T., Schulze, F., Dror, E., Nordmann, T.M., Goetz, N., Koch, N., Dalmas, E., Stawiski, M., Makshana, V., Thorel, F., Herrera, P.L., Boni-Schnetzler, M., Donath, M.Y., Pancreatic alpha cell-derived glucagon-related peptides are required for beta cell adaptation and glucose homeostasis. Cell Rep. 18:13 (2017), 3192–3203.
62. Pospisilik, J.A., Hinke, S.A., Pederson, R.A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U., McIntosh, C.H., Demuth, H., Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul. Pept. 96:3 (2001), 133–141.
63. Muller, T.D., Finan, B., Clemmensen, C., DiMarchi, R.D., Tschop, M.H., The new biology and pharmacology of glucagon. Physiol. Rev. 97:2 (2017), 721–766.
64. Gelling, R.W., Vuguin, P.M., Du, X.Q., Cui, L., Romer, J., Pederson, R.A., Leiser, M., Sorensen, H., Holst, J.J., Fledelius, C., Johansen, P.B., Fleischer, N., McIntosh, C.H., Nishimura, E., Charron, M.J., Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am. J. Physiol. Endocrinol. Metab. 297:3 (2009), E695–E707.
65. Deacon, C.F., Pridal, L., Klarskov, L., Olesen, M., Holst, J.J., Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. 271 (1996), E458–E464.
66. Mentzel, S., Dijkman, H.B., Van Son, J.P., Koene, R.A., Assmann, K.J., Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J. Histochem. Cytochem. 44:5 (1996), 445–461.
67. Tarantola, E., Gobbato, S., Ferrigno, A., Bertone, V., Capelli, E., Differences in expression of DPP4 in steatotic rat liver are not related to differences in the methylation of its gene promoter. In Vivo 29:5 (2015), 547–553.
68. Miyazaki, M., Kato, M., Tanaka, K., Tanaka, M., Kohjima, M., Nakamura, K., Enjoji, M., Nakamuta, M., Kotoh, K., Takayanagi, R., Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol. Med. Rep. 5:3 (2012), 729–733.
69. Zhong, J., Rao, X., Deiuliis, J., Braunstein, Z., Narula, V., Hazey, J., Mikami, D., Needleman, B., Satoskar, A.R., Rajagopalan, S., A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes 62:1 (2013), 149–157.
70. Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E., Gallwitz, B., Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53:3 (2004), 654–662.
71. Nauck, M.A., Meier, J.J., Cavender, M.A., Abd El Aziz, M., Drucker, D.J., Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136:9 (2017), 849–870.
72. Matikainen, N., Manttari, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B.E., Foley, J.E., Taskinen, M.R., Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:9 (2006), 2049–2057.
73. Tremblay, A.J., Lamarche, B., Deacon, C.F., Weisnagel, S.J., Couture, P., Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 13:4 (2011), 366–373.
74. Xiao, C., Dash, S., Morgantini, C., Lewis, G.F., New and emerging regulators of intestinal lipoprotein secretion. Atherosclerosis 233:2 (2014), 608–615.
75. Xiao, C., Dash, S., Morgantini, C., Patterson, B.W., Lewis, G.F., Sitagliptin, a dipeptidyl peptidase-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes 63:7 (2014), 2394–2401.
76. Hsieh, J., Longuet, C., Baker, C.L., Qin, B., Federico, L.M., Drucker, D.J., Adeli, K., The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion. Diabetologia 53:3 (2010), 552–561.
77. Skinner, N.E., Wroblewski, M.S., Kirihara, J.A., Nelsestuen, G.L., Seaquist, E.R., Sitagliptin results in a decrease of truncated apolipoprotein C1. Diabetes Ther. 6:3 (2015), 395–401.
78. Briand, F., Thieblemont, Q., Burcelin, R., Sulpice, T., Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Diabetes Obes. Metab. 14:7 (2012), 662–665.
79. Leiter, L.A., Nauck, M.A., Efficacy and safety of GLP-1 receptor agonists across the spectrum of type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 125:7 (2017), 419–435.
80. Austin, K., Markovic, M.A., Brubaker, P.L., Current and potential therapeutic targets of glucagon-like peptide-2. Curr. Opin. Pharmacol. 31 (2016), 13–18.
81. Hsieh, J., Longuet, C., Maida, A., Bahrami, J., Xu, E., Baker, C.L., Brubaker, P.L., Drucker, D.J., Adeli, K., Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 137:3 (2009), 997–1005.
82. Xiao, C., Dash, S., Morgantini, C., Adeli, K., Lewis, G.F., Gut peptides are novel regulators of intestinal lipoprotein secretion: experimental and pharmacological manipulation of lipoprotein metabolism. Diabetes 64:7 (2015), 2310–2318.
83. Qualmann, C., Nauck, M.A., Holst, J.J., Orskov, C., Creutzfeldt, W., Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol. 32:1 (1995), 13–16.
84. Vella, A., Shah, P., Basu, R., Basu, A., Holst, J.J., Rizza, R.A., Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49:4 (2000), 611–617.
85. Gault, V.A., Flatt, P.R., Harriott, P., Mooney, M.H., Bailey, C.J., O'Harte, F.P., Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J. Endocrinol. 176:1 (2003), 133–141.
86. Drucker, D.J., Shi, Q., Crivici, A., Sumner-Smith, M., Tavares, W., Hill, M., DeForest, L., Cooper, S., Brubaker, P.L., Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15:7 (1997), 673–677.
87. Irwin, N., Gault, V.A., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R., O'Harte, F.P., Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biol. Chem. 386:7 (2005), 679–687.
88. Irwin, N., Green, B.D., Gault, V.A., Harriot, P., O'Harte, F.P., Flatt, P.R., Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. Exp. Gerontol. 41:2 (2006), 151–156.
89. Irwin, N., O'Harte, F.P., Gault, V.A., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R., GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J. Med. Chem. 49:3 (2006), 1047–1054.
90. Kerr, B.D., Flatt, A.J., Flatt, P.R., Gault, V.A., Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 404:3 (2011), 870–876.
91. O'Harte, F.P., Abdel-Wahab, Y.H., Conlon, J.M., Flatt, P.R., Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells. Diabetologia 41:10 (1998), 1187–1193.
92. O'Harte, F.P., Mooney, M.H., Kelly, C.M., Flatt, P.R., Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J. Endocrinol. 165:3 (2000), 639–648.
93. O'Harte, F.P., Mooney, M.H., Kelly, C.M., McKillop, A.M., Flatt, P.R., Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. Regul. Pept. 96:3 (2001), 95–104.
94. O'Harte, F.P., Mooney, M.H., Lawlor, A., Flatt, P.R., N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim. Biophys. Acta 1474:1 (2000), 13–22.
95. Porter, D.W., Irwin, N., Flatt, P.R., Holscher, C., Gault, V.A., Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur. J. Pharmacol. 650:2–3 (2011), 688–693.
96. Finan, B., Ma, T., Ottaway, N., Muller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S.H., Smiley, D.L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., Drucker, D.J., Pfluger, P.T., Perez-Tilve, D., Gidda, J., Vignati, L., Zhang, L., Hauptman, J.B., Lau, M., Brecheisen, M., Uhles, S., Riboulet, W., Hainaut, E., Sebokova, E., Conde-Knape, K., Konkar, A., Dimarchi, R.D., Tschop, M.H., Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5(209), 2013, 10.1126/scitranslmed.3007218.
97. Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K.M., Fischer, K., Campbell, J.E., Sandoval, D., Seeley, R.J., Bleicher, K., Uhles, S., Riboulet, W., Funk, J., Hertel, C., Belli, S., Sebokova, E., Conde-Knape, K., Konkar, A., Drucker, D.J., Gelfanov, V., Pfluger, P.T., Muller, T.D., Perez-Tilve, D., DiMarchi, R.D., Tschop, M.H., A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21:1 (2015), 27–36.
98. Kerr, B.D., Flatt, A.J., Flatt, P.R., Gault, V.A., Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 404:3 (2011), 870–876.
99. Ahren, B., Hughes, T.E., Inhibition of DPP-4 augments insulin secretion in response to exogenously administered GLP-1, GIP, PACAP and GRP in mice. Endocrinology 4 (2005), 2055–2059.
100. Maida, A., Lovshin, J.A., Baggio, L.L., Drucker, D.J., The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances {beta}-cell function but does not inhibit gastric emptying in mice. Endocrinology 149:11 (2008), 5670–5678.
101. Ahren, B., Winzell, M.S., Wierup, N., Sundler, F., Burkey, B., Hughes, T.E., DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Regul. Pept. 143:1–3 (2007), 97–103.
102. Anini, Y., Jarrousse, C., Chariot, J., Nagain, C., Yanaihara, N., Sasaki, K., Bernad, N., Le Nguyen, D., Bataille, D., Roze, C., Oxyntomodulin inhibits pancreatic secretion through the nervous system in rats. Pancreas 20:4 (2000), 348–360.
103. Jarrousse, C., Bataille, D., Jeanrenaud, B., A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. Endocrinology 115 (1984), 102–105.
104. Santoprete, A., Capito, E., Carrington, P.E., Pocai, A., Finotto, M., Langella, A., Ingallinella, P., Zytko, K., Bufali, S., Cianetti, S., Veneziano, M., Bonelli, F., Zhu, L., Monteagudo, E., Marsh, D.J., Sinharoy, R., Bianchi, E., Pessi, A., DPP-IV-resistant, long-acting oxyntomodulin derivatives. J. Pept. Sci. 17:4 (2011), 270–280.